Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check4 days agoChange DetectedAccess to the study record is blocked, as the page now renders a 403 Forbidden error instead of the study details. The interface shows the 403 message and site footer, with the previous content no longer visible.SummaryDifference19%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe revision label on the page has been updated from v3.6.5 to v3.6.6, indicating a newer version of the page content. This is a metadata update and does not affect the study details or participant information.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5, signaling a minor backend/template update to the page.SummaryDifference0.1%

- Check61 days agoChange DetectedType 2 diabetes was added as a topic and 'related topics: MedlinePlus Genetics' were added in the page's contextual links. The site revision label was updated from v3.6.3 to v3.6.4 in the footer.SummaryDifference0.2%

- Check68 days agoChange DetectedType 2 diabetes and related topic references, including MedlinePlus Genetics, have been removed from the page, reducing the explicit disease context shown to readers. The change affects how the study's condition is described and what related resources are visible to users.SummaryDifference0.2%

- Check75 days agoChange DetectedThe page now references Type 2 diabetes more prominently in its related topics and adds MedlinePlus Genetics as a related resource, broadening context and cross-linking to genetic information. This change improves navigation and thematic connections without changing the study's data or primary descriptions.SummaryDifference0.2%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.